Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EQL Pharma AB ( (SE:EQL) ) has shared an update.
EQL Pharma AB has announced that its key product, Mellozzan® (melatonin), has been approved for sale in Turkey by the Turkish Medicines Agency. The product will be manufactured and marketed locally by EQL’s partner, Abdi Ibrahim, with sales expected to begin in the first half of 2026. This approval marks a significant step for EQL Pharma’s expansion into new markets, potentially enhancing its market presence and providing new revenue streams. Additionally, there are plans to expand Mellozzan® with an oral solution in Turkey by 2027, and applications have been submitted for approval in Kazakhstan.
More about EQL Pharma AB
EQL Pharma AB is a company that specializes in developing and selling generic drugs, focusing on niche generics with limited competition. The company operates primarily in the Nordic and European markets, with a significant pipeline of products. EQL Pharma collaborates with leading contract manufacturers and pharmaceutical companies in the EU and Asia, and is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 31,146
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.55B
See more data about EQL stock on TipRanks’ Stock Analysis page.